Regeneron Pharmaceuticals, Inc. share price logo

Regeneron Pharmaceuticals, Inc. Share Price

NASDAQ: REGN

Large Cap

$737.84

-18.89

(-2.50%)

as on

Regeneron Pharmaceuticals, Inc. Stock Performance

as on March 28, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $736.91
    $759.47
    downward going graph

    0.13%

    Downside

    2.93%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $476.49
    $821.11
    downward going graph

    35.42%

    Downside

    11.29%

    Upside

    downward going graph

Regeneron Pharmaceuticals, Inc. share price movements today

Previous Close
$756.73
Open
$756.65
Volume
327.7K
Day's Low - High
$736.91 - $759.47
52 Week Low - High
$476.49 - $821.11

Regeneron Pharmaceuticals, Inc. Historical Returns

1 Month Return
-5.62 %
3 Month Return
-6.02 %
1 Year Return
+ 15.74 %
3 Year Return
-10.79 %
5 Year Return
+ 54.69 %

Regeneron Pharmaceuticals, Inc. Stock Fundamentals & Key Indicators

Check Regeneron Pharmaceuticals, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$80.0B

EPS (TTM)

44.7816

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.03%

PE Ratio (TTM)

18.25

Industry PE ratio

17.836410256410257

PEG Ratio

1.5616

EBITDA

4.2B

Revenue (TTM)

14.3B

Profit Margin

31.41%

Return On Equity TTM

14.86%

Regeneron Pharmaceuticals, Inc. Stock Valuation

Track how Regeneron Pharmaceuticals, Inc. P/E has moved over time to understand its valuation trends.

Regeneron Pharmaceuticals, Inc. in the last 5 years

  • Overview

  • Trends

Lowest (8.61x)

December 31, 2021

Industry (17.84x)

March 28, 2026

Today (18.25x)

March 28, 2026

Highest (24.50x)

September 30, 2024

LowHigh

Today’s Price to Earnings Ratio: 18.25x

Regeneron Pharmaceuticals, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Regeneron Pharmaceuticals, Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$80.0B54.69%18.2531.41%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$43.5B132.92%140.848.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$115.2B101.77%29.5832.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$31.8BNA112.585.37%

Stock Returns calculator for Regeneron Pharmaceuticals, Inc. Stock including INR - Dollar returns

The Regeneron Pharmaceuticals, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Regeneron Pharmaceuticals, Inc. investment value today

Current value as on today

₹1,26,274

Returns

₹26,274

(+26.27%)

Returns from Regeneron Pharmaceuticals, Inc. Stock

₹15,765 (+15.77%)

Dollar Returns*

₹10,509 (+10.51%)

Analyst Recommendation on Regeneron Pharmaceuticals, Inc. Stock

Based on 34 analysts

BUY

76.47%

Buy

20.59%

Hold

2.94%

Sell

Based on 34 analysts, 76.47% of analysts recommend a 'BUY' rating for Regeneron Pharmaceuticals, Inc.. Average target price of $873.24

Regeneron Pharmaceuticals, Inc. Share Price Target

Get share price movements and forecasts by analysts on Regeneron Pharmaceuticals, Inc..

What analysts predicted

15.51%UPSIDE

Target Price

$873.24

Current Price

$737.84

Analyzed by

34 Analysts

Target

$873.24

Regeneron Pharmaceuticals, Inc. target price $873.24, a slight upside of 15.51% compared to current price of $737.84. According to 34 analysts rating.

Regeneron Pharmaceuticals, Inc. Stock’s Investor Sentiment and Interest

Investment in Regeneron Pharmaceuticals, Inc. Shares on INDmoney has dropped by -14.63% over the past 30 days, indicating reduced transactional activity.

Time period: to

Change:-14.63% versus previous 30 day period

Search interest for Regeneron Pharmaceuticals, Inc. Stock has decreased by -15% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-15% versus previous 30 day period

Regeneron Pharmaceuticals, Inc. Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
3,362
3,434
3,145
3,547
3,720
3,789
3,028
3,675
3,754
3,884
Gross Profit
2,820
2,805
2,711
3,066
3,229
3,223
2,564
3,145
3,232
3,299
Operating Income
1,211
1,050
751
1,069
1,179
990
591
1,079
1,026
879
EBITDA
1,234
1,278
830
1,763
1,628
1,095
1,040
1,657
1,919
1,200
Interest Expense
17
18
16
14
13
10
8
3
19
12
Depreciation
105
113
114
120
121
126
126
135
136
145
Income Before Tax
1,110
1,147
700
1,628
1,493
958
905
1,518
1,763
1,043
Income Tax Expense
103
-12
-21
195
152
40
96
127
303
199
Net Income
1,007
1,159
722
1,432
1,340
917
808
1,391
1,460
844
Net Profit Margin
29.97%
33.77%
22.96%
40.38%
36.03%
24.22%
26.70%
37.86%
38.89%
21.74%

Regeneron Pharmaceuticals, Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
4,860
5,872
6,710
7,863
8,497
16,071
12,172
13,117
14,202
14,342
Gross Profit
4,560
5,475
6,276
7,081
7,141
13,348
10,467
12,233
12,231
12,242
Operating Income
1,330
2,079
2,534
2,209
3,576
8,946
5,385
4,047
3,990
3,577
EBITDA
1,435
2,225
2,682
2,420
4,103
9,669
5,259
4,047
5,318
5,818
Interest Expense
7
25
28
30
56
57
59
73
55
43
Depreciation
-
145
148
210
235
286
341
408
482
543
Income Before Tax
1,329
2,078
2,553
2,429
3,810
9,325
4,858
4,199
4,779
5,230
Income Tax Expense
434
880
109
313
297
1,250
520
245
367
725
Net Income
895
1,198
2,444
2,115
3,513
8,075
4,338
3,953
4,412
4,504
Net Profit Margin
18.42%
20.41%
36.42%
26.91%
41.35%
50.25%
35.64%
30.14%
31.07%
31.41%

Regeneron Pharmaceuticals, Inc. Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
1,159
722
1,432
1,340
917
808
1,391
1,460
844
Operating Cash Flow
1,089
1,512
354
1,291
1,262
1,045
1,144
1,618
1,170
Investing Cash Flow
-66
-1,687
-557
-574
350
647
-1,094
-402
220
Financing Cash Flow
-446
47
-478
-634
-1,135
-1,089
-1,128
-717
-780
Change in Cash
577
-128
-681
83
477
604
-1,077
497
610

Regeneron Pharmaceuticals, Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
1,198
2,444
2,115
3,513
8,075
4,338
3,953
4,412
4,504
Operating Cash Flow
1,307
2,195
2,430
2,618
7,081
5,014
4,594
4,420
4,978
Investing Cash Flow
-1,005
-1,463
-2,027
-70
-5,384
-3,784
-3,185
-2,468
-629
Financing Cash Flow
-24
-77
-252
-1,970
-1,005
-1,009
-1,790
-2,200
-3,715
Change in Cash
277
655
150
577
690
221
-381
-248
634

Mutual Funds that own Regeneron Pharmaceuticals, Inc. Stock

Check out the Mutual Funds with significant holdings in Regeneron Pharmaceuticals, Inc..

Global Institutional Holdings in Regeneron Pharmaceuticals, Inc.

Funds
Holdings
BlackRock Inc
8.36%
Amundi
0.85%
Franklin Resources Inc
2.32%
Nuveen, LLC
1.11%
Amvescap Plc.
1.4%
See all

Regeneron Pharmaceuticals, Inc. News & Key Events

  • img

    Today's Timeline - 25 March

    Wed, 09:30 PM

    -

    Regeneron shares surged 31.5% over six months, driven by positive pipeline developments and Dupixent sales growth.

    Wed, 11:37 PM

    -

    Japan approves Dupixent for bullous pemphigoid, expanding its immunology footprint and adding a seventh indication.

    Thu, 01:35 AM

    -

    Regeneron to report Q1 2026 results on April 29, 2026, with a conference call at 8:30 AM ET.

Insights on Regeneron Pharmaceuticals, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Regeneron Pharmaceuticals, Inc. has shown strong growth in its revenue over the last four quarters. Revenue increased from $3.02 billion to $3.88 billion, reflecting an average quarter-on-quarter growth of 7.7%. This consistent upward trend indicates a positive performance for the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 6 months, REGN stock has moved up by 30.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 18.2% return, outperforming this stock by 2.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 68.3% return, outperforming this stock by 79.1%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Regeneron Pharmaceuticals, Inc. has experienced a decline in net profit over the last two quarters. Their net profit decreased from $1.46 billion to $844.6 million, averaging a decrease of 42.2% each quarter.

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
OrganisationRegeneron Pharmaceuticals, Inc.
Headquarters777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707
IndustryHealth Technology
CEODr. Leonard S. Schleifer M.D., Ph.D.
E-voting on sharesClick here to vote

Key Management of Regeneron Pharmaceuticals, Inc.

Name

Title

Mr. Christopher R. Fenimore CPA

Executive VP of Finance & CFO

Mr. Daniel P. Van Plew

Executive VP and GM of Industrial Operations & Product Supply

Mr. Ryan Steinberger

Executive VP, Chief Digital & Technology Officer

Mr. Ryan Crowe

Senior Vice President of Investor Relations & Strategic Analysis

Ms. Sally A. Paull

Executive Vice President of Human Resources

Dr. Leonard S. Schleifer M.D., Ph.D.

Co-Founder, President, CEO & Co-Chairman

Dr. George D. Yancopoulos M.D., Ph.D.

Co-Founder, President, Chief Scientific Officer & Co-Chairman

Mr. Rajesh Ahuja

Senior Vice President of Quality Assurance & Operations

Mr. Joseph J. LaRosa J.D.

Executive VP, General Counsel & Secretary

Ms. Melissa Lozner

Senior VP & Chief Compliance Officer

FAQs

What is Regeneron Pharmaceuticals, Inc. share price today?

Regeneron Pharmaceuticals, Inc. share price today is $737.84 as on at the close of the market. Regeneron Pharmaceuticals, Inc. share today touched a day high of $759.47 and a low of $736.91.

What is the 52 week high and 52 week low for Regeneron Pharmaceuticals, Inc. share?

Regeneron Pharmaceuticals, Inc. share touched a 52 week high of $821.11 on and a 52 week low of $476.49 on . Regeneron Pharmaceuticals, Inc. stock price today i.e. is closed at $737.84,which is 10.14% down from its 52 week high and 54.85% up from its 52 week low.

What is Regeneron Pharmaceuticals, Inc.'s market capitalisation today?

Regeneron Pharmaceuticals, Inc. market capitalisation is $0.08T as on .

How to invest in Regeneron Pharmaceuticals, Inc. Stock (REGN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Regeneron Pharmaceuticals, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Regeneron Pharmaceuticals, Inc. Shares that will get you 0.0020 shares as per Regeneron Pharmaceuticals, Inc. share price of $737.84 per share as on March 28, 2026 at 1:29 am IST.

What is the minimum amount required to buy Regeneron Pharmaceuticals, Inc. Stock (REGN) from India?

Indian investors can start investing in Regeneron Pharmaceuticals, Inc. (REGN) shares with as little as ₹94.651 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹946.51 in Regeneron Pharmaceuticals, Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Regeneron Pharmaceuticals, Inc. share’s latest price of $737.84 as on March 28, 2026 at 1:29 am IST, you will get 0.0136 shares of Regeneron Pharmaceuticals, Inc.. Learn more about fractional shares .

What are the returns that Regeneron Pharmaceuticals, Inc. has given to Indian investors in the last 5 years?

Regeneron Pharmaceuticals, Inc. stock has given 54.69% share price returns and 29.26% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?